Last 12mo stats

mentions

voices

$SLS

Sellas Life Sciences Group

Share on X

$SLS

Sellas Life Sciences Group

Past 12mo:23mentions4voices

Share on X

All voices9 calls since Feb 2026show all

Loading price chart…

Frequently asked

Who mentions $SLS most on Surfaced?

@dustinhuntwn (Dustin) mentions $SLS most — 12 mentions in the past 12 months.

When was $SLS first mentioned on Surfaced?

The earliest tracked mention of $SLS in the Surfaced archive was on Dec 26, 2025.

How many voices track $SLS?

4 FinTwit voices have mentioned $SLS 23 times in the past 12 months.

What kind of voices mention $SLS most?

$SLS is mentioned most by Long Research voices on Surfaced.

Related stocks

$NVAXNovavax

$AIIORobo.ai Inc - Class B

$AIXIXiao-I

$ATAIATAI Life Sciences

Recent calls

9 calls

@adamfeuersteinMay 27, 2026 · 1:57 PM

I have not paid attention to $SLS at all, but I see its management team is touting the delayed arrival of the last death event required to zip up its Phase 3 study as a positive indication of success. To which I say: BWHAHAHAHAHA! Oh lord, has no one learned anything?

Open on X

@dustinhuntwnMay 20, 2026 · 3:46 AM

$SLS Morgan Stanley increasing. BlackRock massively increasing. Mirae increasing. Institutional ownership now above 30% on broader filing-based calculations. REGAL sitting just two events away from the final-analysis trigger. SLS009 continuing to strengthen the story. We are getting incredibly close to what could become one of the most important breakthroughs in oncology for AML patients in years. The market is finally starting to understand how big this setup really is, and I still believe this remains an extraordinary accumulation zone before the full revaluation arrives.

Open on X

@dustinhuntwnMar 27, 2026 · 6:26 AM

$SLS In comparing some other AML trials- Kurosawa CR2, GIMEA/EORTC from the EU, and MD Anderson salvage datasets, one phrase stands out= "CR2 without transplant is generally considered a temporary remission state, not a curative strategy". NO BAT TREATMENT explains why the REGAL trial hasn't hit 80 now virtually 24 months since the last patient was enrolled. Don't let flock of crap and the fat man confuse you.

Open on X

@dustinhuntwnMar 25, 2026 · 3:58 AM

$SLS MOST OVERLOOKED Both the FDA AND the IDMC independently approved unlimited GPS dosing mid-trial. These aren’t rubber stamps. The IDMC sees every patient, every arm, fully unblinded. Their only job is patient safety. The FDA reviewed the full amendment independently. Both concluded that CAPPING doses would HARM patients/unethical Think about that. In AML CR2 — where patients historically survive 5-6 months — GPS patients are alive so long they EXHAUSTED the original 15-dose protocol. Regulators had to rewrite the rules to keep treating them. You don’t get unlimited dosing approved by two independent bodies unless the data screams that patients are alive, responding, and need more GPS. This also converts GPS from a one-time treatment into a chronic maintenance platform — indefinite dosing at $280K+/year per patient across 100,000 AML remission patients, plus 20+ WT1 cancers. The market is pricing this as a binary Phase 3 bet. Is it ? FUK NO!

Open on X

@dustinhuntwnMar 20, 2026 · 2:13 AM

$SLS The fact that, after months of silence, three press releases were issued within just 7 days (March 12: SLS009 patient, March 17: AACR data, March 19: 10-K) is known as “dumping the news.” The company releases all operational updates so the table is “clear” for the one big announcement. Conclusion: The combination of “CEO not receiving RSUs,” “investors massively converting warrants into shares,” and the “nearly completed REGAL study” strongly suggests that we are in the very final phase.

Open on X

@dustinhuntwnMar 16, 2026 · 3:07 AM

$SLS In a trial with 2 arms of 63, 32 deaths sets the median in each arm. Technically the median is set with the death that crosses the KM 50% boundry. However, that only comes into play with dropouts, censors, which would make the median number lower, it can NEVER be higher than 32. Therefore, at IA with 60 deaths in Dec of 2024 the median for BAT was set. 15 months later GPS median still has not been set. BUT if it was set today, the resulting HR would still be under .636. No one wants the trial halted and then end up with a fail and a waste of time and money, but I haven't seen one credible math model to explain how REGAL could fail at this late of a date. Older patients that are AML CR2 status just don't live this long in any great quantity and you would need 25% alive to set the GPS mOS today.

Open on X

@dustinhuntwnMar 10, 2026 · 1:27 AM

$SLS dip then rip tomoroow. Looking for $6.24 to hit. May take a day or two for that to become support. Then $7’s next week. This is going to keep stair stepping up all the way until news hits then the KABOOM https://t.co/x4bV4qSGYF

Open on X

@dustinhuntwnMar 4, 2026 · 1:57 PM

$SLS The SLS setup is pretty unique because you have a small biotech right at the end of a Phase 3 survival trial, with no safety or futility issues, strong Phase 2 data, and events taking longer than expected, which can mean patients are living longer. At the same time, the market cap is still small, so you have a huge catalyst coming while the market hasn’t fully priced it in yet. Most investors see maybe 1–3 setups like this in a decade.

Open on X

@vulturetradesFeb 23, 2026 · 3:43 PM

$SLS straight shot to $5

Open on X